A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia
Australian & New Zealand Journal of Psychiatry April 16, 2024 Samuel P Hatfield, Nicollette Lr Thornton, Kayla Greenstien et al. 9 citations
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change has raised various regulatory concerns and challenges for the field of psychedelic-assisted therapy. To provide clarity, we aimed to comprehensively catalogue the matters relating to psychedelic-assisted therapy that are or could be regulated....